🇺🇸 FDA
Patent

US 10787501

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

granted A61KA61K2039/507A61K39/00

Quick answer

US patent 10787501 (Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/507, A61K39/00, A61K39/15, A61K39/395